10x Genomics (TXG)
(Delayed Data from NSDQ)
$26.90 USD
-0.62 (-2.25%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $26.89 -0.01 (-0.04%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TXG 26.90 -0.62(-2.25%)
Will TXG be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TXG based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TXG
Down -23.92% in 4 Weeks, Here's Why 10x Genomics (TXG) Looks Ripe for a Turnaround
10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy?
TXG: What are Zacks experts saying now?
Zacks Private Portfolio Services
10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know
Here's What Key Metrics Tell Us About 10x Genomics (TXG) Q4 Earnings
10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates
Other News for TXG
Terex Sell Rating Justified by Regional Challenges and Uncertain Growth Prospects
Terex Analysis: Hold Rating Amid Declining Orders and Mixed Financial Signals
Terex Schedules Q1 2024 Financial Results Review Call
Geopolitical Relief Triggers Gold Selloff: Prices Dip Below $2,350 Mark, Mining Stocks Hit Hard
Barclays Keeps Their Hold Rating on Terex (TEX)